Adopting occupational health and safety management standards: The impact on financial performance in pharmaceutical firms in china

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62690094%3A18450%2F20%3A50017042" target="_blank" >RIV/62690094:18450/20:50017042 - isvavai.cz</a>

Result on the web

<a href="https://www.dovepress.com/adopting-occupational-health-and-safety-management-standards-the-impac-peer-reviewed-fulltext-article-RMHP" target="_blank" >https://www.dovepress.com/adopting-occupational-health-and-safety-management-standards-the-impac-peer-reviewed-fulltext-article-RMHP</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2147/RMHP.S261136" target="_blank" >10.2147/RMHP.S261136</a>

Result language

angličtina

Original language name

Adopting occupational health and safety management standards: The impact on financial performance in pharmaceutical firms in china

Original language description

Background and Purpose: In recent years, the frequent occurrence of occupational accidents, illness, and injuries has become a major issue in China. This study aims to investigate the relationship between the adoption of Occupational Health and Safety Management System (OHSMS) standards and financial performance, with a particular focus on the pharmaceutical firms in China. Methods: The study is based on a sample consisting of 125 pharmaceutical firms listed on the Shanghai and the Shenzhen stock exchanges in China for the period 2010–2018. Each sample firm was evaluated by whether and when it is certified by an OHSMS standard depending on secondary data collected from an independent certification database. Panel-based regression models were employed to explore whether adoption of an OHSMS standard has had an impact on financial performance. Results: The regression results reveal that the adoption of an OHSMS standard positively affects contemporaneous financial performance measured by return on assets (ROA), return on equity (ROE), and earnings per share (EPS). Mixed results were found when financial performance indicators were extended by two years, suggesting that ROE will increase in the second year after a firm is certified with the standard, but EPS will decline in the third year. Conclusion: The study findings empirically show that adoption of an OHSMS standard contributes to better financial performance for pharmaceutical firms of China in the short term. However, executives of pharmaceutical firms need to be aware of the increased costs related to certification renewal and audit in the following periods and exercise their management discretion to achieve a win–win situation between OHSMS implementation and financial benefit. © 2020 Yang and Maresova.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30312 - Substance abuse

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Risk Management and Healthcare Policy

ISSN

1179-1594

e-ISSN

—

Volume of the periodical

13

Issue of the periodical within the volume

September

Country of publishing house

NZ - NEW ZEALAND

Number of pages

11

Pages from-to

1477-1487

UT code for WoS article

000569133900001

EID of the result in the Scopus database

2-s2.0-85090653156